DE69429003D1 - Flavonoid und biflavonoid,derivate, pharmazeutische zusammensetzung und ihre anxiolytische wirkung - Google Patents

Flavonoid und biflavonoid,derivate, pharmazeutische zusammensetzung und ihre anxiolytische wirkung

Info

Publication number
DE69429003D1
DE69429003D1 DE69429003T DE69429003T DE69429003D1 DE 69429003 D1 DE69429003 D1 DE 69429003D1 DE 69429003 T DE69429003 T DE 69429003T DE 69429003 T DE69429003 T DE 69429003T DE 69429003 D1 DE69429003 D1 DE 69429003D1
Authority
DE
Germany
Prior art keywords
biflavonoid
flavonoid
derivatives
pharmaceutical composition
anxiolytic effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69429003T
Other languages
English (en)
Other versions
DE69429003T2 (de
Inventor
Bruce Kennedy Cassels
Federico Jose Dajas
Jorge Horacio Medina
Alejandro Constantino Paladini
Rodolfo Horacio Silveira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Strathclyde
Original Assignee
University of Strathclyde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Strathclyde filed Critical University of Strathclyde
Publication of DE69429003D1 publication Critical patent/DE69429003D1/de
Application granted granted Critical
Publication of DE69429003T2 publication Critical patent/DE69429003T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
DE69429003T 1993-08-17 1994-08-17 Flavonoid und biflavonoid,derivate, pharmazeutische zusammensetzung und ihre anxiolytische wirkung Expired - Lifetime DE69429003T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939317071A GB9317071D0 (en) 1993-08-17 1993-08-17 Flavonoids
PCT/GB1994/001803 WO1995005169A1 (en) 1993-08-17 1994-08-17 Flavonoid and biflavonoid derivatives, their pharmaceutical compositions, their anxiolytic activity

Publications (2)

Publication Number Publication Date
DE69429003D1 true DE69429003D1 (de) 2001-12-13
DE69429003T2 DE69429003T2 (de) 2002-07-11

Family

ID=10740608

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69429003T Expired - Lifetime DE69429003T2 (de) 1993-08-17 1994-08-17 Flavonoid und biflavonoid,derivate, pharmazeutische zusammensetzung und ihre anxiolytische wirkung

Country Status (7)

Country Link
US (2) US5756538A (de)
EP (1) EP0714296B1 (de)
JP (1) JPH09501440A (de)
DE (1) DE69429003T2 (de)
ES (1) ES2167375T3 (de)
GB (1) GB9317071D0 (de)
WO (1) WO1995005169A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474994A (en) * 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
US5605896A (en) * 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
EP1245230A3 (de) * 1995-06-23 2003-11-26 Advanced Life Sciences Inc. Amentoflavon als antivirales Mittel
GB9521184D0 (en) * 1995-10-17 1995-12-20 Univ Strathclyde Flavonoids
GB9707013D0 (en) * 1997-04-07 1997-05-28 Univ Strathclyde Halo and/or nitro-substituted flavonoids
US7718694B2 (en) * 1997-10-16 2010-05-18 Children's Hospital & Research Center At Oakland Compositions and methods for therapy for diseases characterized by defective chloride transport
US5972995A (en) * 1997-10-16 1999-10-26 Children's Hospital Medical Center Of Northern California Compositions and methods for cystic fibrosis therapy
KR100395338B1 (ko) * 1999-07-09 2003-08-19 김박광 크리신 유도체 및 이들을 포함한 혈당강하제용 조성물
EP1218002A4 (de) 2000-01-24 2004-09-22 Jozef S Mruk Verwendung von flavon-8-essigsäure bei vaskulären und kardiovaskulären eingriffen und akuten koronaren syndromen
US7183314B1 (en) 2000-07-21 2007-02-27 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
WO2002076241A1 (en) * 2001-03-23 2002-10-03 N.V. Nutricia Preparation for the prevention and/or treatment of altered bone metabolism
US20030165588A1 (en) 2002-03-01 2003-09-04 Unigen Pharmaceuticals, Inc. Identification of free-B-ring flavonoids as potent COX-2 inhibitors
US20050096281A1 (en) * 2002-03-01 2005-05-05 Unigen Pharmaceuticals, Inc. Formulation of a mixture of Free-B-Ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US8034387B2 (en) * 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
WO2003092599A2 (en) * 2002-04-30 2003-11-13 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
US6884783B2 (en) 2002-05-03 2005-04-26 Unigen Pharmaceuticals, Inc. 7-Hydroxy chromones as potent antioxidants
US6740677B2 (en) 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids
WO2004037193A2 (en) * 2002-10-22 2004-05-06 Jenken Biosciences, Inc. Chromones and chromone derivatives and uses thereof
AU2004228021B2 (en) 2003-04-04 2010-09-02 Unigen, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
KR100610562B1 (ko) * 2004-06-28 2006-08-08 재단법인서울대학교산학협력재단 플라보노이드 유도체를 포함하는 급성 또는 만성 퇴행성뇌질환의 예방 또는 치료용 조성물
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
EP1817023A4 (de) * 2004-11-16 2010-08-18 Limerick Biopharma Inc Verfahren und zusammensetzungen zur schmerzbehandlung
TWI454261B (zh) 2007-01-09 2014-10-01 Unigen Inc 作為治療劑之色酮類
EP2117306A4 (de) * 2007-02-14 2010-02-10 Mars Inc Neurogene verbindungen
US7722522B2 (en) * 2008-02-11 2010-05-25 Gregg Alan Klang Brace providing focused energy for medical therapy
BRPI0801239A2 (pt) * 2008-04-01 2009-11-17 Ache Lab Farmaceuticos Sa uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
KR20110033304A (ko) * 2008-07-23 2011-03-30 메사추세츠 인스티튜트 오브 테크놀로지 Ｄｎａ 손상에 대해 보호하고 신경세포 생존을 증가시키는 히스톤 디아세틸라제 1 (ｈｄａｃ1)의 활성화
US9895344B2 (en) * 2008-07-25 2018-02-20 Emory University Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
CN103108633B (zh) 2010-06-09 2016-01-27 爱默蕾大学 TrkB激动剂及其用途
PL2734510T4 (pl) 2011-07-22 2019-05-31 Massachusetts Inst Technology Aktywatory deacetylaz histonowych klasy I (HDAC) i ich zastosowania
WO2014018741A1 (en) 2012-07-27 2014-01-30 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
KR20170100486A (ko) 2014-10-21 2017-09-04 메흐메트 부다크 파파베르 로에아스로부터 수득된 신규 분자를 포함하는 조직 및 세포 염색 제제
US10123991B2 (en) 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
CN108250172A (zh) * 2017-11-22 2018-07-06 中国科学院西北高原生物研究所 一种具有抗焦虑功效的化合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903266A (en) * 1972-05-03 1975-09-02 Ralph C Robbins Compositions and methods for disaggregating blood cells
US4241069A (en) * 1979-09-04 1980-12-23 Miles Laboratories, Inc. 3-Methylene flavanones and 3-methylene chromanones
EP0558245A1 (de) * 1992-02-25 1993-09-01 RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY Heterobicyclische Verbindungen als Alpha-1-Adrenergene und 5HT1A-Rezeptor-Antagonisten

Also Published As

Publication number Publication date
JPH09501440A (ja) 1997-02-10
GB9317071D0 (en) 1993-09-29
WO1995005169A1 (en) 1995-02-23
EP0714296B1 (de) 2001-11-07
ES2167375T3 (es) 2002-05-16
US5756538A (en) 1998-05-26
US6004998A (en) 1999-12-21
EP0714296A1 (de) 1996-06-05
DE69429003T2 (de) 2002-07-11

Similar Documents

Publication Publication Date Title
DE69429003D1 (de) Flavonoid und biflavonoid,derivate, pharmazeutische zusammensetzung und ihre anxiolytische wirkung
EE03680B1 (et) Asendatud püridiinid, nende kasutamine ja farmatseutilised kompositsioonid
NO308298B1 (no) Substituerte kinazolinderivater, anvendelse derav og farmasøytiske preparater inneholdende dem
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
FI943571A0 (fi) 1-bentseenisulfonyyli-1,3-dihydro-2H-bentsimidatsol-2-onijohdannaisia, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
EE04151B1 (et) Atsüülpiperasinüülpürimidiinide derivaadid, nendevalmistamine ja kasutamine ravimitena
ATE243708T1 (de) Substituierte imidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
ATE240315T1 (de) Substituierte 4-amino-2-aryl-pyrimidine, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
ATE222897T1 (de) Substituierte thiazolidinedione derivate, ihre herstellung und pharmazeutische zusammensetzungen,die sie enthalten
ATE303363T1 (de) 4-aminopyridinderivate, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen
DE69704060T2 (de) Tetrahydroisochinolinderivate und ihre pharmazeutische anwendung
DE69524592D1 (de) 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
EE03825B1 (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
DE69618663T2 (de) O-carbamoyl-phenylalaninol-zusammensetzungen und ihre pharmazeutisch anwendbaren salzen
DE59814412D1 (de) Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
FI960867A (fi) Bentsatsepiinijohdannainen, sen farmaseuttinen seos ja välituote
FI951789A (fi) Uusia taksaanijohdannaisia, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
ATE193533T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
EE9900034A (et) Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine
ATE252096T1 (de) Prolylendopeptidase-inhibitoren, ihre herstellung und ihre pharmazeutische verwendung
ATE204266T1 (de) Taxoide, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69415570T2 (de) Esculetin Derivate und pharmazeutische Zusammenstellung
DE60005337D1 (de) Spiroimidazolidinderivate, ihre herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
DE69815244D1 (de) Galactosylierte hydroxyalkylpolysaccharide und ihre derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition